Nuvelo Announces Presentations on Alfimeprase, rNAPc2, and theLeukemia TherapeuticS Program at the American Society of Hematology49th Annual Meeting
SAN CARLOS, Calif., November 12, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that data from the Phase 3 SONOMA-2 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase- 2) trial evaluating alfimeprase in catheter occlusion (CO), preclinical data evaluating recombinant nematode anticoagulant protein c2 (rNAPc2) in mouse models of colorectal cancer, and preclinical data from the leukemia therapeutic antibody program, will be presented at the American Society of Hematology (ASH) 49th Annual Meeting, in Atlanta, GA, December 8-11, 2007.
The presentation details are as follows: Date/Time: Saturday, December 8, 2007, 5:30 p.m. ET Poster Session (1792): IREM-1 Is a Cell Surface Receptor Expressed in AML Blasts: Potential for Targeted Immunotherapy in AML Date/Time: Saturday, December 8, 2007, 5:30 p.m. ET Poster Session (923): rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, Inhibits Tumor Growth and Metastasis in Mouse Models of Colorectal Cancer Date/Time: Sunday, December 9, 2007, 6:00 p.m. ET Poster Session (1866): Safety and Efficacy of Alfimeprase in Subjects with Occluded Central Venous Access Devices: The SONOMA-2 Study Date/Time: Monday, December 10, 2007, 5:00 p.m. ET Poster Session (2839): CLL-1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia
All abstracts will appear in the November 16, 2007 issue of Blood, The Journal of The American Society of Hematology.
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes alfimeprase, a direct acting fibrinolytic in Phase 2 clinical development for the treatment of thrombotic-related disorders including acute ischemic stroke and catheter occlusion; and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a potential short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to continue its research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.
This press release contains "forward-looking statements," which include statements regarding the timing and progress of Nuvelo's clinical stage and research programs, the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; stock market conditions; the impact of competitive products and technological changes; and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10Q for the quarter ended September 30, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
Posted: November 2007